239 related articles for article (PubMed ID: 9093887)
1. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers in patients with chronic renal failure.
Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
[TBL] [Abstract][Full Text] [Related]
3. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
Odagiri E; Jibiki K; Takeda M; Sugimura H; Iwachika C; Abe Y; Kihara K; Kihara Y; Itou M; Nomura T
Am J Nephrol; 1991; 11(5):363-8. PubMed ID: 1725572
[TBL] [Abstract][Full Text] [Related]
4. Tumor markers in chronic renal failure and hemodialysis patients.
Cases A; Filella X; Molina R; Ballesta AM; Lopez-Pedret J; Revert L
Nephron; 1991; 57(2):183-6. PubMed ID: 2020345
[TBL] [Abstract][Full Text] [Related]
5. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
6. [Use of tumor markers in patients on chronic hemodialysis].
Kuno T; Kaizu K
Nihon Rinsho; 2004 Jun; 62 Suppl 6():391-4. PubMed ID: 15250332
[No Abstract] [Full Text] [Related]
7. Measurement of tumor markers in chronic hemodialysis patients.
Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.
Nomura F; Koyama A; Ishijima M; Takano S; Narita M; Nakai T
Oncol Rep; 1998; 5(2):389-92. PubMed ID: 9468564
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor markers in hemodialysis patients.
Maoujoud O; El Machtani S; Asseraji M; Atbib Y; Zajjari Y; Taoufik A; Elbouaiti E; Zouhair O; Benyahia M; Tellal S
Int J Artif Organs; 2014 Feb; 37(2):126-32. PubMed ID: 24619900
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers in patients undergoing hemodialysis or kidney transplantation.
Zeferos N; Digenis GE; Christophoraki M; Alexopoulos I; Kostakis A; Gyftaki H; Moulopoulos S
Nephron; 1991; 59(4):618-20. PubMed ID: 1722565
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor markers in patients on dialysis and kidney transplantation.
Lye WC; Tambyah P; Leong SO; Lee EJ
Adv Perit Dial; 1994; 10():109-11. PubMed ID: 7528056
[TBL] [Abstract][Full Text] [Related]
12. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
13. [Application of multiple tumor markers's protein chip in the screen program of the elderly].
Yan HY; Zhong RH; Li J; Luo XH; Chen R
Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Sep; 32(9):924-6. PubMed ID: 22340884
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
Lee JH; Chang JH
Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of abnormal levels of serum tumour markers in elderly people.
Lopez LA; Del Villar V; Ulla M; Fernandez F; Fernandez LA; Santos I; Rabadan L; Gutierrez M
Age Ageing; 1996 Jan; 25(1):45-50. PubMed ID: 8670528
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
18. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
20. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
